parthenolide has been researched along with Cognitive Decline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, M; Jiang, Y; Wang, C; Zhao, X | 1 |
| Chen, F; Duan, Y; Li, G; Li, L; Liang, G; She, L; Sun, J; Tang, H; Wang, W; Xiong, L; Zeng, Y; Zhao, X | 1 |
2 other study(ies) available for parthenolide and Cognitive Decline
| Article | Year |
|---|---|
Parthenolide alleviates microglia-mediated neuroinflammation via MAPK/TRIM31/NLRP3 signaling to ameliorate cognitive disorder.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents; Cognitive Dysfunction; Cytokines; Lipopolysaccharides; Mice; Mice, Transgenic; Microglia; Neuroinflammatory Diseases; NLR Family, Pyrin Domain-Containing 3 Protein | 2023 |
Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3β(Ser9)/Nrf2 signaling pathway.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animals; Cognitive Dysfunction; Glycogen Synthase Kinase 3 beta; Mice; Neuroprotective Agents; Neurotoxicity Syndromes; NF-E2-Related Factor 2; Rats; Reactive Oxygen Species; Signal Transduction | 2023 |